ROCKET PHARMACEUTICALS, INC. (RCKT)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch RCKT
See up to 3 months of RCKT. The 7-day demo opens the 1M and 3M ranges and puts RCKT on your watchlist.
Start 7-day demoLatest RCKT insider trades
About ROCKET PHARMACEUTICALS, INC. (RCKT)
ROCKET PHARMACEUTICALS, INC. files with the SEC under CIK 0001281895 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
RCKT Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 7 | 125,977 | $432K |
| Grant or award | 2 | 174,741 | |
| Other acquisition / disposition | 1 | 150,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
RCKT insider transactions (Form 4)
5592 Form 4 filings on record, the earliest from Oct 29, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Martin Wilson - Officer | Open-market sale | Common Stock | 75,364 | $3.40 | $256K | |
| Martin Wilson - Officer | Open-market sale | Common Stock | 631 | $3.38 | $2K | |
| Gaurav Shah - Officer | Open-market sale | Common Stock | 2,293 | $3.38 | $8K | |
| Gaurav Shah - Officer | Open-market sale | Common Stock | 2,837 | $3.38 | $10K | |
| Martin Wilson - Officer | Open-market sale | Common Stock | 3,493 | $3.38 | $12K | |
 Christopher James Stevens - Officer | Open-market sale | Common Stock | 36,658 footnote F2 | $3.50 | $128K | |
| ||||||
| Sarbani Chaudhuri - Officer | Open-market sale | Common Stock | 4,701 | $3.50 | $16K | |
| Christopher James Stevens - Officer | Grant or award | Common Stock | 73,313 footnote F2 | $0.00 | - | |
| Christopher James Stevens - Officer | Grant or award | Stock Option (Right to Buy) | 101,428 | $0.00 | - | |
| ||||||
| David P. Southwell - Director | Other | Common Stock | 150,000 | $0.00 footnote F2 | - | |
| ||||||
 Roderick Wong | Grant or award | Common Stock | 27,832 | $0.00 footnote F1 | - | |
| Roderick Wong | Grant or award | Stock Option (Right to Buy) | 78,960 | $0.00 | - | |
| ||||||
 Peter Fong | Grant or award | Common Stock | 22,862 | $0.00 footnote F2 | - | |
| Peter Fong | Grant or award | Stock Option (Right to Buy) | 64,860 | $0.00 | - | |
| ||||||
| Mikael Dolsten | Grant or award | Common Stock | 22,862 | $0.00 footnote F2 | - | |
| Mikael Dolsten | Grant or award | Stock Option (Right to Buy) | 64,860 | $0.00 | - | |
| ||||||
| Fady Ibraham Malik | Grant or award | Common Stock | 22,862 | $0.00 footnote F1 | - | |
| Fady Ibraham Malik | Grant or award | Stock Option (Right to Buy) | 64,860 | $0.00 | - | |
| ||||||
| David P. Southwell | Grant or award | Common Stock | 22,862 | $0.00 footnote F1 | - | |
| David P. Southwell | Grant or award | Stock Option (Right to Buy) | 64,860 | $0.00 | - | |
| ||||||
| Carsten Boess | Grant or award | Common Stock | 22,862 | $0.00 footnote F1 | - | |
| Carsten Boess | Grant or award | Stock Option (Right to Buy) | 64,860 | $0.00 | - | |
| ||||||
| John Militello - Officer | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F1 | - | |
| John Militello - Officer | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F1 | - | |
| John Militello - Officer | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F1 | - | |
| John Militello - Officer | Derivative | Stock Option (Right to Buy) | 20,000 | - footnote F1 | - | |
| John Militello - Officer | Derivative | Stock Option (Right to Buy) | 20,000 | - footnote F1 | - | |
| John Militello - Officer | Derivative | Stock Option (Right to Buy) | 2,000 | - footnote F1 | - | |
| John Militello - Officer | Derivative | Stock Option (Right to Buy) | 18,000 | - footnote F1 | - | |
| John Militello - Officer | Derivative | Stock Option (Right to Buy) | 18,000 | - footnote F1 | - | |
| John Militello - Officer | Derivative | Stock Option (Right to Buy) | 27,003 | - footnote F1 | - | |
| John Militello - Officer | Derivative | Stock Option (Right to Buy) | 28,910 | - footnote F1 | - | |
| John Militello - Officer | Derivative | Stock Option (Right to Buy) | 49,798 | - footnote F1 | - | |
| John Militello - Officer | Derivative | Stock Option (Right to Buy) | 24,545 | - footnote F1 | - | |
| John Militello - Officer | Grant or award | Stock Option (Right to Buy) | 51,509 | - footnote F1 | - | |
| John Militello - Officer | Grant or award | Stock Option (Right to Buy) | 15,002 | - footnote F1 | - | |
| John Militello - Officer | Grant or award | Stock Option (Right to Buy) | 16,061 | - footnote F1 | - | |
| John Militello - Officer | Grant or award | Stock Option (Right to Buy) | 24,899 | - footnote F1 | - | |
| John Militello - Officer | Grant or award | Stock Option (Right to Buy) | 9,091 | - footnote F1 | - | |
| ||||||
| Gaurav Shah - Officer | Option exercise | Common Stock | 76,490 | $1.69 | $129K | |
| Gaurav Shah - Officer | Option exercise | Stock Option (Right to Buy) | 76,490 | $1.69 | $129K | |
| Gaurav Shah - Officer | Open-market sale | Common Stock | 55,684 | $3.09 footnote F4 | $172K | |
| ||||||
| Gaurav Shah - Officer | Open-market sale | Common Stock | 2,409 | $3.01 | $7K | |
| Martin Wilson - Officer | Open-market sale | Common Stock | 662 | $3.01 | $2K | |
| John Militello - Officer | Open-market sale | Common Stock | 384 | $3.01 | $1K | |
| Martin Wilson - Officer | Open-market sale | Common Stock | 3,361 | $3.61 | $12K | |
| Gaurav Shah - Officer | Open-market sale | Common Stock | 2,728 | $3.61 | $10K | |
| John Militello - Officer | Open-market sale | Common Stock | 855 | $3.61 | $3K | |
| Sarbani Chaudhuri - Officer | Open-market sale | Common Stock | 17,650 | $3.84 | $68K | |
| John Militello - Officer | Open-market sale | Common Stock | 1,157 | $3.34 | $4K | |
| Gaurav Shah - Officer | Open-market sale | Common Stock | 5,990 | $3.34 | $20K | |
| Martin Wilson - Officer | Open-market sale | Common Stock | 1,376 | $3.34 | $5K | |
| Martin Wilson - Officer | Open-market sale | Common Stock | 12,253 | $3.31 | $41K | |
| John Militello - Officer | Open-market sale | Common Stock | 3,726 | $3.31 | $12K | |
| Gaurav Shah - Officer | Open-market sale | Common Stock | 12,279 | $3.31 | $41K | |
Item 1.01, 2.03, 3.02, 7.01, 9.01
Item 7.01, 9.01
Item 5.02
Item 2.02, 9.01
Recent RCKT Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Militello John | Former Officer | 6,897 | $23K | View on EDGAR | |
| Militello John | Former Officer | 6,857 |
RCKT insider trading FAQ
What is the latest insider trade for RCKT?
ROCKET PHARMACEUTICALS, INC. (RCKT) had 9 insider filings in the last 90 days, with the most recent on 2026-09-16. The full record for RCKT runs to 92 Form 4 filings, the earliest from 2024-10-29. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying RCKT stock?
No insider purchases of RCKT were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling RCKT stock?
7 insider sales of RCKT were filed in the last 90 days, totaling $432K.
Where can I see RCKT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects RCKT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Martin Wilson view on EDGAR
- - Martin Wilson view on EDGAR
- - Gaurav Shah view on EDGAR
- - Gaurav Shah view on EDGAR
- - Martin Wilson view on EDGAR
- - Christopher James Stevens view on EDGAR
- - Sarbani Chaudhuri view on EDGAR
- - Christopher James Stevens view on EDGAR
- - David P. Southwell view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where RCKT's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow RCKT with a 7-day demo
- RCKT on your watchlist
- Every RCKT Form 4 filing on record
- Up to 3 months of RCKT price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
